Published in Nature on April 07, 2005
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol (2007) 3.16
Insulin resistance and atherosclerosis. J Clin Invest (2006) 2.27
Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol (2009) 2.23
Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A (2008) 1.97
An exploratory prospective study of marijuana use and mortality following acute myocardial infarction. Am Heart J (2008) 1.97
Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A (2006) 1.95
Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem (2009) 1.91
Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology (2010) 1.82
The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest (2008) 1.82
CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol (2007) 1.77
Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol (2007) 1.65
Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res (2011) 1.60
Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J (2013) 1.59
CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol (2007) 1.55
The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J (2005) 1.50
Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest (2011) 1.46
Association of coronary artery and aortic calcium with lumbar bone density: the MESA Abdominal Aortic Calcium Study. Am J Epidemiol (2008) 1.45
Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med (2009) 1.44
Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer (2012) 1.41
Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A (2006) 1.41
Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med (2009) 1.38
Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol (2007) 1.34
Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci (2008) 1.32
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol (2007) 1.32
CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol (2007) 1.32
Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Mol Pharmacol (2008) 1.31
Cannabinoids in health and disease. Dialogues Clin Neurosci (2007) 1.28
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci (2012) 1.27
The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol (2007) 1.25
Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One (2009) 1.25
The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem (2007) 1.24
The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol (2009) 1.24
Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol (2007) 1.24
GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res (2011) 1.21
CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. Br J Pharmacol (2010) 1.18
Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation (2012) 1.15
Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience (2013) 1.14
Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS. J Neuroimmune Pharmacol (2010) 1.10
Inactivation of lipid glyceryl ester metabolism in human THP1 monocytes/macrophages by activated organophosphorus insecticides: role of carboxylesterases 1 and 2. Chem Res Toxicol (2010) 1.09
Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes (2011) 1.08
Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension (2008) 1.07
Formation of B and T cell subsets require the cannabinoid receptor CB2. Immunogenetics (2006) 1.05
Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic pain. J Neurosci (2008) 1.05
Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III. BMJ Open (2012) 1.04
Bone mineral density and atherosclerosis: the Multi-Ethnic Study of Atherosclerosis, Abdominal Aortic Calcium Study. Atherosclerosis (2009) 1.03
Peroxisomal and microsomal lipid pathways associated with resistance to hepatic steatosis and reduced pro-inflammatory state. J Biol Chem (2010) 1.03
Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol (2007) 1.01
Cannabinoid receptors in acute and chronic complications of atherosclerosis. Br J Pharmacol (2007) 1.00
Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J Neurosci (2012) 1.00
The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev (2011) 0.99
Cardiac and vascular phenotypes in the apolipoprotein E-deficient mouse. J Biomed Sci (2012) 0.99
Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. Br J Pharmacol (2010) 0.97
Endocannabinoids and the haematological system. Br J Pharmacol (2007) 0.94
The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. Br J Pharmacol (2011) 0.94
Endocannabinoids and the heart. J Cardiovasc Pharmacol (2009) 0.94
Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol (2013) 0.93
Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Front Behav Neurosci (2011) 0.91
Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol (2007) 0.91
The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J (2011) 0.91
Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns? Arterioscler Thromb Vasc Biol (2009) 0.90
Cannabinoid (CB2) receptor deficiency reduces the susceptibility of macrophages to oxidized LDL/oxysterol-induced apoptosis. J Lipid Res (2008) 0.90
The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am J Pathol (2011) 0.89
Production of the endocannabinoids anandamide and 2-arachidonoylglycerol by endothelial progenitor cells. FEBS Lett (2007) 0.88
Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice. Atherosclerosis (2010) 0.87
Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies. Br J Pharmacol (2012) 0.86
Anticancer mechanisms of cannabinoids. Curr Oncol (2016) 0.86
In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans. Eur J Nucl Med Mol Imaging (2007) 0.85
β-Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner. Free Radic Biol Med (2012) 0.85
Update on the role of cannabinoid receptors after ischemic stroke. Mediators Inflamm (2012) 0.85
Anti-inflammatory cannabinoids in diet: Towards a better understanding of CB(2) receptor action? Commun Integr Biol (2008) 0.84
Chemical Atherogenesis: Role of Endogenous and Exogenous Poisons in Disease Development. Toxics (2015) 0.83
Cannabinoid Receptor 2 Deficiency in Haematopoietic cells Aggravates Early Atherosclerosis in LDL Receptor Deficient Mice. Open Cardiovasc Med J (2011) 0.83
Cannabinoid receptor CB2 protects against balloon-induced neointima formation. Am J Physiol Heart Circ Physiol (2012) 0.83
Cyclooxygenase metabolism mediates vasorelaxation to 2-arachidonoylglycerol (2-AG) in human mesenteric arteries. Pharmacol Res (2014) 0.83
Cannabinoid receptor 2 signaling does not modulate atherogenesis in mice. PLoS One (2011) 0.82
Atherosclerosis is an inflammatory disease. Semin Immunopathol (2009) 0.82
The cannabinoid WIN55,212-2 protects against oxidized LDL-induced inflammatory response in murine macrophages. J Lipid Res (2010) 0.82
Activation of cannabinoid receptor 2 enhances osteogenic differentiation of bone marrow derived mesenchymal stem cells. Biomed Res Int (2015) 0.81
Marijuana use and long-term mortality among survivors of acute myocardial infarction. Am Heart J (2012) 0.81
Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration. Toxicol Lett (2012) 0.81
Activation of cannabinoid receptor 2 inhibits experimental cystitis. Am J Physiol Regul Integr Comp Physiol (2013) 0.81
Molecular MRI of Inflammation in Atherosclerosis. Curr Cardiovasc Imaging Rep (2011) 0.81
Targeted zwitterionic near infrared fluorescent probe for improved imaging of type 2 cannabinoid receptors. J Biomed Opt (2014) 0.80
Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration: implications for atherosclerosis and inflammatory diseases. Am J Physiol Heart Circ Physiol (2008) 0.80
The CB2 receptor and its role as a regulator of inflammation. Cell Mol Life Sci (2016) 0.79
Carboxylesterases: Dual roles in lipid and pesticide metabolism. J Pestic Sci (2010) 0.79
AM-251 and SR144528 are acyl CoA:cholesterol acyltransferase inhibitors. Biochem Biophys Res Commun (2009) 0.78
Recreational drug use and risk of Kaposi's sarcoma in HIV- and HHV-8-coinfected homosexual men. AIDS Res Hum Retroviruses (2009) 0.78
Oxyradical Stress, Endocannabinoids, and Atherosclerosis. Toxics (2015) 0.78
Monoglyceride lipase deficiency modulates endocannabinoid signaling and improves plaque stability in ApoE-knockout mice. Atherosclerosis (2015) 0.78
Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists. Bioorg Med Chem (2014) 0.77
Primary Macrophage Chemotaxis Induced by Cannabinoid Receptor 2 Agonists Occurs Independently of the CB2 Receptor. Sci Rep (2015) 0.77
Cannabis exposure as an interactive cardiovascular risk factor and accelerant of organismal ageing: a longitudinal study. BMJ Open (2016) 0.76
Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling. Pharmacol Ther (2017) 0.75
Treatment with CB2 agonist JWH-133 reduces histological features associated with erectile dysfunction in hypercholesterolemic mice. Clin Dev Immunol (2013) 0.75
De Novo Lipogenesis Products and Endogenous Lipokines. Diabetes (2016) 0.75
Pharmacology: marijuana and your heart. Nature (2005) 0.75
Cannabinoid Receptor Type 2 (CB2) Dependent and Independent Effects of WIN55,212-2 on Atherosclerosis in Ldlr-null Mice. J Cardiol Ther (2015) 0.75
Rimonabant is a dual inhibitor of acyl CoA:cholesterol acyltransferases 1 and 2. Biochem Biophys Res Commun (2010) 0.75
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet (2006) 4.01
A humanized version of Foxp2 affects cortico-basal ganglia circuits in mice. Cell (2009) 3.63
GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science (2004) 3.38
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder. Am J Hum Genet (2011) 2.71
[Statin treatment in primary and secondary prevention--a statement]. Rev Med Suisse (2014) 2.55
Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis (2009) 2.54
Interaction with vesicle luminal protachykinin regulates surface expression of delta-opioid receptors and opioid analgesia. Cell (2005) 2.52
Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J Neurosci (2002) 2.24
Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest (2013) 2.23
Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci U S A (2003) 2.21
An ancient genome duplication contributed to the abundance of metabolic genes in the moss Physcomitrella patens. BMC Evol Biol (2007) 2.17
A role for ASIC3 in the modulation of high-intensity pain stimuli. Proc Natl Acad Sci U S A (2002) 2.11
Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology (2005) 2.07
F3/contactin acts as a functional ligand for Notch during oligodendrocyte maturation. Cell (2003) 2.05
Inferior vena cava parameters predict re-admission in ischaemic heart failure. Eur J Clin Invest (2014) 2.01
Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2006) 1.99
Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res (2003) 1.99
Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A (2008) 1.97
Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A (2006) 1.95
Introducing the German Mouse Clinic: open access platform for standardized phenotyping. Nat Methods (2005) 1.93
Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation (2004) 1.90
HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS (2009) 1.88
Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology (2010) 1.82
Attenuation of allergic contact dermatitis through the endocannabinoid system. Science (2007) 1.70
A practical note on the use of cytotoxicity assays. Int J Pharm (2004) 1.63
The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study. AIDS (2004) 1.63
The specific role of chemokines in atherosclerosis. Thromb Haemost (2007) 1.62
Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation (2012) 1.57
Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study. J Gastroenterol Hepatol (2011) 1.57
Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res (2005) 1.49
Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol (2005) 1.49
A tarantula peptide against pain via ASIC1a channels and opioid mechanisms. Nat Neurosci (2007) 1.49
Receptor activator of NF- κB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. Thromb Haemost (2011) 1.48
The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci (2005) 1.47
Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci (2006) 1.46
Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J (2009) 1.44
Mouse phenotyping. Methods (2010) 1.43
Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology (2011) 1.41
Late cardiac tamponade after percutaneous closure of a patent foramen ovale. Eur J Echocardiogr (2005) 1.41
Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation (2009) 1.41
An unusual cause of cholecystitis. Gastroenterology (2012) 1.40
Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation (2005) 1.40
Pancreatitis-associated acute lung injury: new insights. Chest (2003) 1.40
Genome-wide association-, replication-, and neuroimaging study implicates HOMER1 in the etiology of major depression. Biol Psychiatry (2010) 1.39
Stairs instead of elevators at workplace: cardioprotective effects of a pragmatic intervention. Eur J Cardiovasc Prev Rehabil (2010) 1.33
Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci (2008) 1.32
Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol (2012) 1.32
Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation (2006) 1.31
A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol (2008) 1.30
B-Raf acts via the ROCKII/LIMK/cofilin pathway to maintain actin stress fibers in fibroblasts. Mol Cell Biol (2004) 1.28
Neuronal 3',3,5-triiodothyronine (T3) uptake and behavioral phenotype of mice deficient in Mct8, the neuronal T3 transporter mutated in Allan-Herndon-Dudley syndrome. J Neurosci (2009) 1.28
Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. J Comp Neurol (2008) 1.25
Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One (2009) 1.25
CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol (2008) 1.25
CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol (2009) 1.24
Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. Circulation (2003) 1.22
NB-3/Notch1 pathway via Deltex1 promotes neural progenitor cell differentiation into oligodendrocytes. J Biol Chem (2004) 1.22
Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med (2005) 1.22
Altered pattern of vascular connexin expression in atherosclerotic plaques. Arterioscler Thromb Vasc Biol (2002) 1.21
A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy. Hum Mutat (2008) 1.21
Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. J Mol Cell Cardiol (2009) 1.20
Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis (2006) 1.19
A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking. J Neurosci (2003) 1.17
Tumor necrosis factor-alpha (TNF-alpha) induces integrin CD11b/CD18 (Mac-1) up-regulation and migration to the CC chemokine CCL3 (MIP-1alpha) on human neutrophils through defined signalling pathways. Cell Signal (2007) 1.16
Cardiovascular consequences of sleep-disordered breathing: contribution of animal models to understanding the human disease. ILAR J (2009) 1.16
Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology (2007) 1.15
Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine (2008) 1.15
The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost (2009) 1.14
Cytotoxicity of nanoparticles independent from oxidative stress. J Toxicol Sci (2009) 1.13